Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Dose reduction and discontinuation of non-tumor necrosis factor (TNF) biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for people with rheumatoid arthritis in remission or low disease activity.
Journal: The Cochrane database of systematic reviews
Published: May 20, 2026
Immune hallmarks of recurrent immune checkpoint inhibitor-mediated inflammatory arthritis.
Journal: Cancer immunology research
Published: December 23, 2025
Summary recommendations from the NCI clinical trials planning meeting (CTPM) on advanced cutaneous squamous cell carcinoma in immunosuppressed patients.
Journal: Journal of the National Cancer Institute
Published: August 05, 2025
Managing Rheumatoid Arthritis in Older Adults with Cancer.
Journal: Drugs & aging
Published: May 06, 2025
Author Correction: Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.
Journal: Nature communications
Published: July 04, 2024
Case of new-onset scleromyxoedema-scleroedema spectrum disorder in a patient with CLL.
Journal: RMD open
Published: November 02, 2023
Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors.
Journal: Cancers
Published: July 11, 2023
Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events.
Journal: Journal for immunotherapy of cancer
Published: May 07, 2023
Durvalumab-associated generalized morphea with overlapping vitiligo.
Journal: JAAD case reports
Published: November 21, 2022
Bupropion XL and SR have similar effectiveness and adverse event profiles when used to treat smoking among patients at a comprehensive cancer center.
Journal: The American journal on addictions
Published: November 08, 2021
Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma.
Journal: Journal of immunotherapy and precision oncology
Published: August 28, 2021
Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab.
Journal: Journal for immunotherapy of cancer
Published: May 28, 2021
Last Updated: 09/26/2026